Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13342937 | 1.00 | CFTR (0.47) | CFTRMAPTTBK1PDE4BGPR119 | |
| SCHEMBL5184376 | 0.89 | PDE4D (0.44) | CFTRMAPTPDE4BPDE4DPDE4A | |
| SCHEMBL13342922 | 0.85 | PDE4A (0.45) | CFTRMAPTTBK1PDE4BPDE4D | |
| SCHEMBL3616052 | 0.85 | PDE4A (0.45) | CFTRMAPTTBK1PDE4BPDE4D | |
| SCHEMBL8233537 | 0.83 | CFTR (0.50) | CFTRMAPTGPR119SMPD3LMNA | |
| SCHEMBL13342944 | 0.83 | ACVR1 (0.44) | TBK1PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3602812 | 0.83 | ACVR1 (0.44) | TBK1PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3612890 | 0.81 | PDE4D (0.53) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL13342924 | 0.81 | PDE4D (0.53) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL13343030 | 0.80 | PDE4A (0.52) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | claimed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | claimed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CFTR 825/4885MAPT 3815/4885TBK1 4034/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | CFTR 825/4885MAPT 3815/4885TBK1 4034/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CFTR 825/4885MAPT 3815/4885TBK1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.